Abstract
BackgroundSingle-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have